You can buy or sell NVUS and other stocks, options, ETFs, and crypto commission-free!
Novus Therapeutics, Inc. Common Stock, also called Novus Therapeutics, is a pharmaceutical company, which engages in the acquisition, development, and commercialization of products for disorders of the ear, nose, and throat. Read More Its product pipelines include OPO201; OP0101; and OP0102. The company was founded on March 26, 2004 and is headquartered in Irvine, CA.
52 Week High
52 Week Low
Tuesday 5/7 Insider Buying Report: NLY, NVUS
Bargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their hard-earned dollars to make a purchase, is that they expect to make money.
Yahoo FinanceMay 2
Novus Therapeutics Announces Closing of $10.7 Million Registered Direct Offering Priced At-the-Market
IRVINE, Calif.--(BUSINESS WIRE)-- Novus Therapeutics, Inc. (NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced the closing of its previously announced registered direct offering of 3,449,112 shares of its common stock, at a purchase price per share of $3.095, priced at-the-market, to healthcare-focused institutional investors, led by OrbiMed, BVF Partners L.P., and Armistice Capital. Novus also issued unr...
-$0.48 per share
-$0.52 per share